TEVA

Teva Pharmaceutical-sp Adr

-$1.9B

Net Activity

Institutions Holding

664

Popularity Rank

#787

Avg Weight

0.35%

Total Value

$21.2B

Ownership Trend

664 institutions currently hold TEVA, with 325 net buyers and 275 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

275

Net Buying Institutions

325

Key Holders

View all 664 holding institutions

Quarterly Activity

Recent Activity

+$16.3B

Total Buy Value

$8.7B

Total Sell Value

New buy83
Trim205
Add242
Sold out70

325

Net Buyers

275

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding TEVA PHARMACEUTICAL-SP ADR (TEVA)?
Major stakeholders currently include BlackRock, Inc. ($2.0B), Harel Insurance Investments & Financial Services Ltd. ($1.4B), Phoenix Financial Ltd. ($1.3B). Based on the latest 13F filings, there are a total of 664 tracked investment funds and institutions maintaining positions in TEVA.
What is the overall institutional sentiment toward TEVA recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $1.9B, driven by 325 managers accumulating shares while 275 reduced their exposure.
Which institutions have been selling or reducing their TEVA positions?
In the latest period, 205 funds trimmed their holdings, and 70 managers completely exited their positions. The aggregate reported sell value was $8.7B.
Are there any notable investors adding TEVA to their portfolios?
Yes, buying activity remains notable. 83 institutions opened new positions in {ticker}, and 242 existing holders added to their shares. The total reported buy value for the quarter amounted to $16.3B.

Related Stocks